Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing beta-galactosylation azo ene glycol and preparation method thereof

A technology for the alkylation of azodiol and galactose, which is applied in the direction of preparation of sugar derivatives, esterification of saccharides, chemical instruments and methods, etc., can solve the problems of accelerated degradation, environmental temperature and humidity sensitivity, and organs that do not reach the level of drugs Dosage and other issues, to achieve the effect of prolonging the release time and good tissue specificity

Active Publication Date: 2013-04-03
BEIJING UNIV OF CHEM TECH
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, β-galactosylated azocenediol is sensitive to ambient temperature and humidity, and can only be stored at 4 °C for about 10 days. + also accelerates its degradation
If the form of a single drug is used, β-galactosylated azocenediol is easy to release NO in advance when it is stored in the external environment or transported in the body, which affects all organs and sometimes produces serious side effects and complications. In NO-deficient organs, effective drug doses are not achieved

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing beta-galactosylation azo ene glycol and preparation method thereof
  • Pharmaceutical composition containing beta-galactosylation azo ene glycol and preparation method thereof
  • Pharmaceutical composition containing beta-galactosylation azo ene glycol and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Combination drug components: 7g β-galactosylated azocenediol, 5g magainin, 70g sodium montmorillonite, 18g monostearyl polyglycerol ester with a polymerization degree of 6-14.

[0030] Combination drug preparation:

[0031] 1) Take 8g of magainin and dissolve it in 20ml of ethanol aqueous solution, the volume ratio of ethanol to water is 1:4, then add 70g of montmorillonite, stir to make the magainin fully adsorbed in the montmorillonite, filter, Take the montmorillonite, evaporate the alcohol, and put it into an oven for drying;

[0032] 2) Take 10g of β-galactosylated azocenediol and dissolve it in 25ml of ethanol, then add the montmorillonite adsorbed with magainin obtained in step 1), and stir to make the NO donor drug fully adsorbed on In the montmorillonite, filter, take the montmorillonite, and evaporate the alcohol;

[0033] 3) Add 18g of polyglycerol monostearate to the montmorillonite adsorbed with magainin and NO donor drug obtained in step 2), and mix well t...

Embodiment 2

[0035] Combination drug components: 12g of β-galactosylated azocenediol, 7g of magainin, 60g of sodium montmorillonite, and 21g of polydimethylsiloxane with a specific gravity of 0.96-0.97.

[0036] Combination drug preparation:

[0037] 1) Take 10g of magainin and dissolve it in 35ml of ethanol aqueous solution, the volume ratio of ethanol to water is 3:7, then add 60g of montmorillonite, stir to make the magainin fully adsorbed in the montmorillonite, filter, Take the montmorillonite, evaporate the alcohol, and put it into an oven for drying;

[0038] 2) Dissolve 16g of β-galactosylated azocenediol in 30ml of ethanol, then add the montmorillonite adsorbed with gliacinin obtained in step 1), and stir to make the NO donor drug fully adsorbed on In the montmorillonite, filter, take the montmorillonite, and evaporate the alcohol;

[0039] 3) Add 21g of stearyl polyglycerol ester to the montmorillonite adsorbed with magainin and NO donor drug obtained in step 2), and mix well t...

Embodiment 3

[0041] Combination drug components: 30g of β-galactosylated azocenediol, 4g of magainin, 50g of calcium montmorillonite, and 16g of ethyl cellulose with a molecular weight of 2000.

[0042] Combination drug preparation:

[0043] 1) Take 6g of magainin and dissolve it in 30ml of ethanol aqueous solution, the volume ratio of ethanol to water is 1:4, then add 50g of calcium montmorillonite, stir to make the magainin fully adsorbed in the montmorillonite, filter , take the montmorillonite, evaporate the alcohol, and put it into an oven for drying;

[0044] 2) Take 30g of β-galactosylated azocenediol and dissolve it in 80ml of ethanol, then add the montmorillonite adsorbed with magainin obtained in step 1), and stir to make the NO donor drug fully adsorbed on In the montmorillonite, filter, take the montmorillonite, and evaporate the alcohol;

[0045] 3) Add 16 g of ethyl cellulose to the montmorillonite adsorbed with magainin and NO donor drug obtained in step 2), and mix well t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
degree of polymerizationaaaaaaaaaa
Login to View More

Abstract

The invention relates to the technical field of medical pharmaceutical engineering, relates to a pharmaceutical composition containing an NO donor and a preparation method thereof, in particular to a pharmaceutical composition containing beta-galactosylation azo ene glycol and a preparation method thereof. The pharmaceutical composition containing beta-galactosylation azo ene glycol provided by the invention comprises NO donor medicine containing beta-galactosylation azo ene glycol, sperm of xenopus laevis, montmorillonite and moisture-proofing agent; and the preparation method of the pharmaceutical composition comprises the following steps of: dissolving sperm of xenopus laevis in alcoholic solution, adding montmorllonite, fully stirring, filtering the montmorillonite, and drying; dissolving the NO donor medicine containing beta-galactosylation azo ene glycol in alcohol, then adding the montmorllonite, fully stirring, filtering the montmorillonite, volatilizing the alcohol and then adding the moisture-proofing agent, and mixing evenly, thus the pharmaceutical composition containing beta-galactosylation azo ene glycol is obtained. The pharmaceutical composition containing beta-galactosylation azo ene glycol provided by the invention is waterproof and antiacid, release time of the NO donor can be prolonged, and stable and controllable aims are achieved.

Description

technical field [0001] The invention belongs to the technical field of medical pharmaceutical engineering, and relates to a combination medicine containing NO donor and a preparation method thereof, in particular to a combination medicine containing β-galactosylated azocenediol and a preparation method thereof. Background technique [0002] Nitric oxide (NO) is a gaseous small molecular substance with various biological activities. In the body, NO and L-guanidine are produced from NO precursor substance L-arginine under the catalysis of nitric oxide synthase (NOS) and oxygen molecules. NO is ubiquitous in various cells of vertebrates, such as endothelial cells, macrophages, and nerve cells. It is an important regulator of intercellular and intracellular information transmission, and is also a cytotoxic factor in the host immune response. It has been proven to have a variety of biological activities, including regulation of vasodilation and blood flow, nerve signal transmiss...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/16A61K31/7024C07H13/06C07H1/00A61P31/04A61P31/12A61K33/06
Inventor 陈畅邓玲玲张会萍田婕
Owner BEIJING UNIV OF CHEM TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com